These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 9657443)
1. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Clark P; Brennand J; Conkie JA; McCall F; Greer IA; Walker ID Thromb Haemost; 1998 Jun; 79(6):1166-70. PubMed ID: 9657443 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of smoking as a risk factor for activated protein C resistance during pregnancy. Kafkas S; Kalkan U; Bolaman Z; Sanci M; Yüksel H; Odabaşi AR Gynecol Obstet Invest; 2007; 64(2):89-94. PubMed ID: 17314487 [TBL] [Abstract][Full Text] [Related]
3. Haemostatic changes and acquired activated protein C resistance in normal pregnancy. Mahieu B; Jacobs N; Mahieu S; Naelaerts K; Vertessen F; Weyler J; Jacquemyn Y; Van der Planken M Blood Coagul Fibrinolysis; 2007 Oct; 18(7):685-8. PubMed ID: 17890957 [TBL] [Abstract][Full Text] [Related]
4. Longitudinal evaluation of activated protein C resistance among normal pregnancies of Hispanic women. Fassett MJ; Bohn YC; Kuo J; Wing DA Am J Obstet Gynecol; 2000 Jun; 182(6):1433-6. PubMed ID: 10871461 [TBL] [Abstract][Full Text] [Related]
5. The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: significance of pregnancy associated activated protein C resistance. Clark P; Sattar N; Walker ID; Greer IA Thromb Haemost; 2001 Jan; 85(1):30-5. PubMed ID: 11204583 [TBL] [Abstract][Full Text] [Related]
6. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614 [TBL] [Abstract][Full Text] [Related]
7. Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000). Gardiner C; Machin SJ; Mackie IJ Int J Lab Hematol; 2008 Aug; 30(4):261-8. PubMed ID: 18665822 [TBL] [Abstract][Full Text] [Related]
8. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463 [TBL] [Abstract][Full Text] [Related]
10. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays. Favaloro EJ; Mirochnik O; McDonald D Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912 [TBL] [Abstract][Full Text] [Related]
11. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables. Lowe GD; Rumley A; Woodward M; Reid E; Rumley J Thromb Haemost; 1999 Jun; 81(6):918-24. PubMed ID: 10404768 [TBL] [Abstract][Full Text] [Related]
12. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation. De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766 [TBL] [Abstract][Full Text] [Related]
13. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis. Mosnier LO; Meijers JC; Bouma BN Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322 [TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity. Strandberg K; Svensson PJ; Ohlin AK Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343 [TBL] [Abstract][Full Text] [Related]
15. A plasma coagulation assay for an activated protein C-independent anticoagulant activity of protein S. van Wijnen M; van 't Veer C; Meijers JC; Bertina RM; Bouma BN Thromb Haemost; 1998 Dec; 80(6):930-5. PubMed ID: 9869163 [TBL] [Abstract][Full Text] [Related]
16. Detecting APC-resistant factor V: a functional method without plasma dilution. Rylatt DB; Hohnen-Behrens C; Pilgrim RL; Dickeson LE; Neal M; Exner T Blood Coagul Fibrinolysis; 1999 Sep; 10(6):359-66. PubMed ID: 10493217 [TBL] [Abstract][Full Text] [Related]
17. Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy. Choi JW; Pai SH Ann Hematol; 2002 Nov; 81(11):611-5. PubMed ID: 12454697 [TBL] [Abstract][Full Text] [Related]
18. Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period. Ohashi R; Sugimura M; Kawamura T; Tamura N; Kanayama N Acta Obstet Gynecol Scand; 2005 Aug; 84(8):799-801. PubMed ID: 16026408 [TBL] [Abstract][Full Text] [Related]
19. Functional and immunologic protein S in normal pregnant women and in full-term newborns. Fernández JA; Estellés A; Gilabert J; España F; Aznar J Thromb Haemost; 1989 Jun; 61(3):474-8. PubMed ID: 2529662 [TBL] [Abstract][Full Text] [Related]
20. Altered reference ranges for protein C and protein S during early pregnancy: Implications for the diagnosis of protein C and protein S deficiency during pregnancy. Said JM; Ignjatovic V; Monagle PT; Walker SP; Higgins JR; Brennecke SP Thromb Haemost; 2010 May; 103(5):984-8. PubMed ID: 20174758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]